MLchartDataset catalogue

crisaborole ointment

Term · Oncology and biomedicine · MLC-T-ONC-012804

A topical ointment formulation composed of crisaborole, a boron-containing phosphodiesterase 4 (PDE4) inhibitor, with potential immunomodulating activity. Upon topical administration of the crisaborole ointment to the affected area(s), crisaborole targets, binds to and inhibits PDE4, which increases intracellular cyclic adenosine monophosphate (cAMP) levels. This decreases inflammation in the skin. PDE4 inhibition may reduce cetuximab-related skin toxicity and atopic dermatitis.

Table 1. Record
IdentifierMLC-T-ONC-012804
FieldOncology and biomedicine
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-012804",
  "term": "crisaborole ointment",
  "field": "Oncology and biomedicine",
  "definition": "A topical ointment formulation composed of crisaborole, a boron-containing phosphodiesterase 4 (PDE4) inhibitor, with potential immunomodulating activity. Upon topical administration of the crisaborole ointment to the affected area(s), crisaborole targets, binds to and inhibits PDE4, which increases intracellular cyclic adenosine monophosphate (cAMP) levels. This decreases inflammation in the skin. PDE4 inhibition may reduce cetuximab-related skin toxicity and atopic dermatitis.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/crisaborole-ointment/"
}

Record 5,431 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.